Tafasitamab (Minjuvi®) in combination with lenalidomide. HTA ID: 22008

Assessment Status Rapid Review Complete
HTA ID 22008
Drug Tafasitamab
Brand Minjuvi®
Indication In combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem-cell transplant (ASCT).
Assessment Process
Rapid review commissioned 14/02/2022
Rapid review completed 15/02/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tafasitamab in combination with lenalidomide compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.